EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Promise and Peril of a Genotype‐First Approach to Mendelian Cardiovascular Disease

Babken Asatryan iD, Brittney Murray iD, Rafik Tadros iD, Marina Rieder, Ravi A Shah iD, Ghaith Sharaf Dabbagh iD, Andrew P Landstrom iD, Stephan Dobner iD, Patricia B Munroe iD, Christopher M Haggerty iD, Argelia Medeiros-Domingo iD, Anjali T Owens iD und 9 weitere

Journal of the American Heart Association · 2024

DOI: 10.1161/jaha.123.033557 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Babken Asatryan und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine Johns Hopkins University School of Medicine Baltimore MD USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Genetic Testing, Genetic Predisposition to Disease. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Precision medicine, which among other aspects includes an individual's genomic data in diagnosis and management, has become the standard‐of‐care for Mendelian cardiovascular disease (CVD). However, early identification and management of asymptomatic patients with potentially lethal and manageable Mendelian CVD through screening, which is the promise of precision health, remains an unsolved challenge. The reduced costs of genomic sequencing have enabled the creation of biobanks containing in‐depth genetic and health information, which have facilitated the understanding of genetic variation, penetrance, and expressivity, moving us closer to the genotype‐first screening of asymptomatic individuals for Mendelian CVD. This approach could transform health care by diagnostic refinement and facilitating prevention or therapeutic interventions. Yet, potential benefits must be weighed against the potential risks, which include evolving variant pathogenicity assertion or identification of variants with low disease penetrance; costly, stressful, and inappropriate diagnostic evaluations; negative psychological impact; disqualification for employment or of competitive sports; and denial of insurance. Furthermore, the natural history of Mendelian CVD is often unpredictable, making identification of those who will benefit from preventive measures a priority. Currently, there is insufficient evidence that population‐based genetic screening for Mendelian CVD can reduce adverse outcomes at a reasonable cost to an extent that outweighs the harms of true‐positive and false‐positive results. Besides technical, clinical, and financial burdens, ethical and legal aspects pose unprecedented challenges. This review highlights key developments in the field of genotype‐first approaches to Mendelian CVD and summarizes challenges with potential solutions that can pave the way for implementing this approach for clinical care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesGenetic TestingGenetic Predisposition to DiseaseHumansPrecision MedicineGenotypeRisk AssessmentPhenotype

Stichwörter der Autor:innen

biobankcardiac arrhythmiacardiomyopathygeneticsprecision healthprecision medicine sudden cardiac death

Autor:innen und Institutionen

  • Division of Cardiology, Department of Medicine Johns Hopkins University School of Medicine Baltimore MD USA.
  • Department of Cardiology Inselspital, Bern University Hospital, University of Bern Bern Switzerland.
  • Cardiovascular Genetics Centre Montréal Heart Institute Montréal Québec Canada.
  • Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust London United Kingdom.
  • Center for Inherited Cardiovascular Diseases WellSpan Health Lancaster PA USA.
  • Division of Cardiovascular Medicine University of Michigan Ann Arbor MI USA.

ORCID-Profile: Babken Asatryan, Brittney Murray, Rafik Tadros, Ravi A Shah, Ghaith Sharaf Dabbagh, Andrew P Landstrom, Stephan Dobner, Patricia B Munroe, Christopher M Haggerty, Argelia Medeiros-Domingo, Anjali T Owens, Iftikhar J Kullo, Christopher Semsarian, Tobias Reichlin, Andreas S Barth, Dan M Roden, Cynthia A James, James S Ware, C Anwar A Chahal

Zitieren

APA

Asatryan, B., Murray, B., Tadros, R., Rieder, M., Shah, R. A., Sharaf Dabbagh, G., Landstrom, A. P., Dobner, S., Munroe, P. B., Haggerty, C. M., Medeiros-Domingo, A., Owens, A. T., Kullo, I. J., Semsarian, C., Reichlin, T., Barth, A. S., Roden, D. M., James, C. A., Ware, J. S., …, & Genotype‐First Approach Investigators (2024). Promise and Peril of a Genotype‐First Approach to Mendelian Cardiovascular Disease. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.033557

Vancouver

Asatryan B, Murray B, Tadros R, Rieder M, Shah RA, Sharaf Dabbagh G, et al. Promise and Peril of a Genotype‐First Approach to Mendelian Cardiovascular Disease. Journal of the American Heart Association. 2024. doi:10.1161/jaha.123.033557

BibTeX
@article{Asatryan2024,
  author = {Asatryan, Babken and Murray, Brittney and Tadros, Rafik and Rieder, Marina and Shah, Ravi A and Sharaf Dabbagh, Ghaith and Landstrom, Andrew P and Dobner, Stephan and Munroe, Patricia B and Haggerty, Christopher M and Medeiros-Domingo, Argelia and Owens, Anjali T and Kullo, Iftikhar J and Semsarian, Christopher and Reichlin, Tobias and Barth, Andreas S and Roden, Dan M and James, Cynthia A and Ware, James S and Chahal, C Anwar A and Genotype‐First Approach Investigators, Genotype‐First Approach Investigators},
  title = {Promise and Peril of a Genotype‐First Approach to Mendelian Cardiovascular Disease},
  journal = {Journal of the American Heart Association},
  year = {2024},
  doi = {10.1161/jaha.123.033557}
}
Kostenlos starten →